moxifloxacin antibiotic used treat bacterial including pneumonia conjunctivitis endocarditis tuberculosis given mouth injection vein eye common side effects include diarrhea dizziness severe side effects may include spontaneous tendon ruptures nerve damage worsening myasthenia safety use pregnancy breastfeeding moxifloxacin fluoroquinolone family usually kills bacteria blocking ability duplicate moxifloxacin patented approved use united states world health organizations list essential moxifloxacin treats number infections including respiratorytract infections cellulitis anthrax intraabdominal infections endocarditis meningitis united states moxifloxacin licensed treatment acute bacterial sinusitis acute bacterial exacerbation chronic bronchitis communityacquired pneumonia complicated uncomplicated infections skin skin structure complicated intraabdominal european union licensed acute bacterial exacerbations chronic bronchitis nonsevere communityacquired pneumonia acute bacterial sinusitis basis investigation reports rare severe cases liver toxicity skin reactions european medicines agency recommended use oral intravenous form moxifloxacin restricted infections antibacterial agents used united states marketing approval contain restrictions though label contains prominent warnings skin reactions initial approval food drug administration united states december encompassed indications additional indications approved food drug administration european medicines agency advised pneumonia acute bacterial sinusitis acute exacerbations copd used antibiotics oral intravenous moxifloxacin approved children several drugs class including moxifloxacin licensed food drug administration use children risk permanent injury musculoskeletal moxifloxacin eye drops approved conjunctival infections caused susceptible recently alarming reports moxifloxacin resistance rates among anaerobes published austria bacteroides reported resistant italy resistance rates high broad spectrum bacteria susceptible including following rare serious adverse effects may occur result moxifloxacin therapy include irreversible peripheral neuropathy spontaneous tendon rupture hepatitis psychiatric effects hallucinations depression torsades de pointes syndrome clostridium difficileassociated photosensitivityphototoxicity several reports suggest use moxifloxacin may lead exposure developing fetus quinolones including levofloxacin firsttrimester associated increased risk stillbirths premature births birth defects low birth limited data appearance moxifloxacin human breastmilk animal studies found moxifloxacin appears significant concentration decisions whether continue therapy pregnancy breast feeding take potential risk harm fetus child account well importance drug wellbeing two listed contraindications found within package insert though stated within package insert ziprasidone also considered contraindicated may potential prolong qt interval moxifloxacin also avoided patients uncorrected hypokalemia concurrent administration medications known prolong qt interval antipsychotics tricyclic moxifloxacin used caution patients diabetes glucose regulation may significantly moxifloxacin also considered contraindicated within pediatric population pregnancy nursing mothers patients history tendon disorder patients documented qt patients epilepsy seizure disorders coadministration moxifloxacin drugs also prolong qt interval induce bradycardia eg betablockers amiodarone avoided careful consideration given use moxifloxacin patients cardiovascular disease including conduction safety moxifloxacin human patients age established animal studies suggest risk musculoskeletal harm moxifloxacin believed associated clinically significant drug interactions due inhibition stimulation hepatic metabolism thus part require special clinical laboratory monitoring ensure moxifloxacin potential serious drug interaction combination corticosteroids moxifloxacin increased potential result tendonitis antacids containing aluminium magnesium ions inhibit absorption moxifloxacin drugs prolong qt interval eg pimozide may additive effect qt prolongation lead increased risk ventricular arrhythmias international normalised ratio may increased decreased patients treated event acute overdose stomach emptied adequate hydration maintained ecg monitoring recommended due possibility qt interval prolongation patient carefully observed given supportive treatment administration activated charcoal soon possible oral overdose may prevent excessive increase systemic moxifloxacin exposure dose moxifloxacin well glucuronide metabolite removed continuous ambulatory peritoneal dialysis hemodialysis respectively quoting december package insert moxifloxacin broadspectrum antibiotic active grampositive gramnegative bacteria functions inhibiting dna gyrase type ii topoisomerase topoisomerase enzymes necessary separate bacterial dna thereby inhibiting cell replication oral intravenous dose moxifloxacin metabolized via glucuronide sulfate conjugation cytochrome system involved moxifloxacin metabolism affected sulfate conjugate accounts around dose eliminated primarily feces approximately oral intravenous dose converted glucuronide conjugate excreted exclusively urine peak plasma concentrations parent drug plasma concentrations general less vitro studies cytochrome cyp enzymes indicate moxifloxacin inhibit suggesting moxifloxacin unlikely alter pharmacokinetics drugs metabolized pharmacokinetics moxifloxacin pediatric subjects elimination halflife moxifloxacin hours singledose oral intravenous dose moxifloxacin excreted unchanged drug urine feces total oral dose excreted either unchanged drug known metabolites mean sd apparent total body clearance renal clearance lh lh csf penetration moxifloxacin patients moxifloxacin monohydrochloride slightly yellow yellow crystalline synthesized several steps first involving preparation racemic resolved using tartaric acid suitably derivatised quinolinecarboxylic acid introduced presence dabco followed acidification form moxifloxacin moxifloxacin first patented united states patent bayer ag avelox subsequently approved us food drug administration fda use united states treat specific bacterial ranking within top prescribed drugs united states avelox generated sales million moxifloxacin also manufactured alcon united states patent application made june avelox bayer ag assignee subsequently approved february patent scheduled expire june however patent extended additional two one half years september expected expire moxifloxacin subsequently ten years later approved fda use united states least four additional united states patents filed regarding moxifloxacin hydrochloride since united states well patents outside us regulatory agencies taken actions address certain rare serious adverse events associated moxifloxacin therapycitation needed based investigation reports rare severe cases liver toxicity skin reactions european medicines agency recommended use oral iv form moxifloxacin restricted infections antibacterial agents used similarly canadian label includes warning risk liver us label contain restrictions similar european label carries black box warning risk tendon damage andor rupture warnings regarding risk irreversible peripheral us district court district delaware held two bayer patents avelox valid enforceable infringed dr reddys anda generic version district court sided bayer citing federal circuits prior decision takeda v affirming district courts finding defendant failed prove prima facie case obviousness prior art disclosed broad selection compounds one could selected lead compound investigation defendant prove prior art would led selection particular compound singled defendant according bayers press announcing courts decision noted teva also challenged validity bayer patents issue dr reddys case within bayers firstquarter stockholders bayer stated reached agreement teva pharmaceuticals usa inc adverse party settle patent litigation regard two bayer patents settlement terms agreed upon teva would obtain license sell generic moxifloxacin tablet product us shortly second two bayer patents expires march bangladesh available brand name optimoxcitation needed httpsenwikipediaorgwikimoxifloxacin